Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 3
1970 4
1971 1
1972 4
1973 2
1974 2
1975 6
1976 9
1977 5
1978 8
1979 7
1980 6
1981 6
1982 2
1983 6
1984 16
1985 16
1986 12
1987 17
1988 7
1989 10
1990 11
1991 25
1992 14
1993 24
1994 20
1995 9
1996 18
1997 29
1998 29
1999 25
2000 26
2001 28
2002 25
2003 21
2004 27
2005 29
2006 27
2007 10
2008 18
2009 6
2010 3
2011 9
2012 3
2013 3
2015 1
2016 5
2017 2
2018 1
2019 1
2021 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

591 results
Results by year
Filters applied: . Clear all
Page 1
Preface.
Breedveld FC, Kalden JR, Smolen JS. Breedveld FC, et al. Among authors: kalden jr. Semin Arthritis Rheum. 2019 Dec;49(3S):S1-S2. doi: 10.1016/j.semarthrit.2019.10.004. Epub 2019 Oct 31. Semin Arthritis Rheum. 2019. PMID: 31706626 No abstract available.
[Biologics].
Kalden JR. Kalden JR. Z Rheumatol. 2016 Aug;75(6):604-10. doi: 10.1007/s00393-016-0122-2. Z Rheumatol. 2016. PMID: 27365024 Review. German. No abstract available.
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Lipsky PE, et al. Among authors: kalden jr. N Engl J Med. 2000 Nov 30;343(22):1594-602. doi: 10.1056/NEJM200011303432202. N Engl J Med. 2000. PMID: 11096166 Free article. Clinical Trial.
Advances in targeted therapies 2017.
Breedveld FC, Kalden JR, Smolen JS. Breedveld FC, et al. Among authors: kalden jr. Clin Immunol. 2018 Jan;186:1-2. doi: 10.1016/j.clim.2018.01.007. Epub 2018 Jan 31. Clin Immunol. 2018. PMID: 29378299 No abstract available.
Advances in targeted therapy.
Breedveld FC, Kalden JR, Smolen JS. Breedveld FC, et al. Among authors: kalden jr. Rheumatology (Oxford). 2016 Dec;55(suppl 2):ii1-ii2. doi: 10.1093/rheumatology/kew354. Rheumatology (Oxford). 2016. PMID: 27856653 No abstract available.
Emerging Therapies for Rheumatoid Arthritis.
Kalden JR. Kalden JR. Rheumatol Ther. 2016 Jun;3(1):31-42. doi: 10.1007/s40744-016-0032-4. Epub 2016 Jun 3. Rheumatol Ther. 2016. PMID: 27747522 Free PMC article. Review.
What triggers anti-dsDNA antibodies?
Herrmann M, Zoller OM, Hagenhofer M, Voll R, Kalden JR. Herrmann M, et al. Among authors: kalden jr. Mol Biol Rep. 1996;23(3-4):265-7. doi: 10.1007/BF00351179. Mol Biol Rep. 1996. PMID: 9112239 Review.
Lefunomide in combination therapy.
Kalden JR, Smolen JS, Emery P, van Riel PL, Dougados M, Strand CV, Breedveld FC. Kalden JR, et al. J Rheumatol Suppl. 2004 Jun;71:25-30. J Rheumatol Suppl. 2004. PMID: 15170905 Review.
Perspectives for TNF-alpha-targeting therapies.
Lorenz HM, Kalden JR. Lorenz HM, et al. Among authors: kalden jr. Arthritis Res. 2002;4 Suppl 3(Suppl 3):S17-24. doi: 10.1186/ar564. Epub 2002 May 9. Arthritis Res. 2002. PMID: 12110119 Free PMC article. Review.
SLE--a disease of clearance deficiency?
Munoz LE, Gaipl US, Franz S, Sheriff A, Voll RE, Kalden JR, Herrmann M. Munoz LE, et al. Among authors: kalden jr. Rheumatology (Oxford). 2005 Sep;44(9):1101-7. doi: 10.1093/rheumatology/keh693. Epub 2005 May 31. Rheumatology (Oxford). 2005. PMID: 15928001 Review.
591 results